Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

NCT05663827 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yi-Lun Wang